Latest

4 stories

Hide weekly roundups

Tuesday, September 8

Braveheart Bio starts Phase 3 oHCM trial, reports Q2 2026 results

The company began its LIONHEART-HCM Phase 3 study in obstructive hypertrophic cardiomyopathy and reported $122.8 million in cash as of June 30, 2026, rising to $527.3 million after its August IPO.

SEC filing

Monday, August 10

Braveheart Bio registers Phase 3 trial of BHB-1893 for obstructive HCM

Trial updateBHB-1893 Braveheart Bio, Inc.

Thursday, August 6

FinancingBraveheart Bio, Inc.

Braveheart Bio prices IPO at $18 per share, raising $382.5 million

The clinical-stage cardiovascular biotech offered 21,250,000 shares ahead of Nasdaq debut under ticker "BRVE."

SEC filing

Tuesday, July 14

FinancingBHB-1893 Braveheart Bio, Inc.

Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893

The clinical-stage company has raised about $185 million to date and plans to start its oHCM Phase 3 trial in the second half of 2026, with an nHCM trial to follow in early 2027.

SEC filing